Sequenom→LabCorp
Acquisition · Cash · LH · announced Jul 27, 2016
Announced
Jul 27, 2016
Closed
Sep 6, 2016
Economics
Cash()
Pre-deal · pre-deal mark: 2016, year precision · LabCorp 8-K filing, SEC EDGAR — Sequenom acquisition
Enterprise value ~$371M including net debt ($302M equity value at $2.40/share)
Target
Sequenom
Diagnostics · Diagnostic / genomic
HQ San Diego, CA · Founded 2000
Pioneer in non-invasive prenatal testing (NIPT) — MaterniT21 test for fetal chromosomal abnormalities, over 500K tests performed
- SEC EDGAR - LabCorp/Sequenom merger filing (Jul 27, 2016)
- Business Wire - acquisition announcement
Acquirer
LabCorp (LH)
Diagnostics
HQ Burlington, NC
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Created market leader in NIPT — MaterniT21 test complemented LabCorp's women's health and reproductive genetics offering; over 500K tests performed at time of deal
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR — LabCorp/Sequenom merger filing (Jul 27, 2016)
SEC EDGAR filings (ticker locator)Primary (regulatory / filing)
SEC EDGAR 8-K https://www.sec.gov/Archives/edgar/data/920148/000119312516660283/d200155d8k.htm
Open source
Limitations
- Single-source or weak corroboration — treat valuation and timing as directional.
- Enterprise value ~$371M including net debt ($302M equity value at $2.40/share)
- Pre-deal valuation sourced from: LabCorp 8-K filing, SEC EDGAR — Sequenom acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| EUROIMMUN | PerkinElmer (Revvity) | Jun 16, 2017 | same evidence class | |
| Counsyl | Myriad Genetics | May 28, 2018 | same evidence class | |
| nVision Medical | Boston Scientific | Apr 16, 2018 | same evidence class |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Alere | Abbott Laboratories | Feb 1, 2016 |
Other verified deals by LabCorp
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Ovia Health | LabCorp | Aug 12, 2021 | Undisclosed | Maternal Health |
Patient empowerment context
Empowerment context — Sequenom
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Not recommended genetic testing (NCCN: almost all should)37%cited HLTH 2022
Other curated mappings on these gaps: Biotheranostics, Endomagnetics, Genomic Health, Foundation Medicine
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.